Drug profile · INN
ketorolac tromethamine
ACULAR LS
ketorolac tromethamine (ACULAR LS) is a cyclooxygenase inhibitor. Associated with Amphastar France Pharmaceuticals. Route of administration: nasal. Current US regulatory status: approved.
Drug details — ketorolac tromethamine
- US status
- approved
- Class
- —
- Route
- NASAL
- Patents
- 20
- Programs
- 118
- Data quality
- 0.89
Quick answer
ketorolac tromethamine (ACULAR LS) is a cyclooxygenase inhibitor. Associated with Amphastar France Pharmaceuticals. Route of administration: nasal. Current US regulatory status: approved.
Key facts
Mechanism of action
Cyclooxygenase inhibitor
Primary target: Cyclooxygenase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12344842
Compositions and methods for treating and preventing macular degeneration
granted -
US 12116622
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
granted -
US 12097188
Compositions and methods for the treatment of macular degeneration
granted -
US 12084515
Compositions and methods for treatment of diabetic macular edema
granted -
US 11969401
Compositions and methods for treating or limiting development of age-related macular degeneration
granted -
US 11769597
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
granted -
US 11519020
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
granted -
US 11046785
Compositions and methods for treatment of diabetic macular edema
granted -
US 11040055
Method of treating diabetic retinopathy or wet type adult macular degeneration
granted -
US 10968278
Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
granted -
US 10905770
Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases
granted -
US 2020339710
GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF
granted -
US 2020239601
CROSSLINKED POLYMERIC NETWORK AND USE THEREOF
granted -
US 10640771
Compositions and methods for treating and preventing macular degeneration
granted -
US 10426817
Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
granted -
US 10111862
Traps in the treatment of macular degeneration
granted -
US 10000753
Age-related macular degeneration treatment
granted -
US 9861600
Methods and compositions for treating and identifying compounds to treat age-related macular degeneration treatment
granted -
US 9814701
Compositions and methods for the treatment of macular degeneration
granted -
US 9795673
Treating macular degeneration using antibodies to aminophospholipids
granted
Frequently asked questions
What is ketorolac tromethamine?
ketorolac tromethamine (ACULAR LS) is a cyclooxygenase inhibitor. Associated with Amphastar France Pharmaceuticals. Route of administration: nasal. Current US regulatory status: approved.
What is the brand name for ketorolac tromethamine?
ACULAR LS is a marketed brand name for ketorolac tromethamine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ketorolac tromethamine?
ketorolac tromethamine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.